Journal article

Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World

Cole B Hirschfeld, Leslee J Shaw, Michelle C Williams, Ryan Lahey, Todd C Villines, Sharmila Dorbala, Andrew D Choi, Nishant R Shah, David A Bluemke, Daniel S Berman, Ron Blankstein, Maros Ferencik, Jagat Narula, David Winchester, Eli Malkovskiy, Benjamin Goebel, Michael J Randazzo, Juan Lopez-Mattei, Purvi Parwani, Joao V Vitola Show all

JACC-CARDIOVASCULAR IMAGING | ELSEVIER SCIENCE INC | Published : 2021

Abstract

OBJECTIVES: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. BACKGROUND: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. METHODS: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions ..

View full abstract

Grants

Funding Acknowledgements

This work was supported by the International Atomic Energy Agency. Dr. Blankstein has previously received research support from Amgen and Astellas Inc. Dr. Ferencik has been previously supported by U.S. National Institutes of Health (NIH) and American Heart Association; and is a consultant for Biograph, Inc. Dr. NOrgaard has previously received unrestricted institutional research grants from Siemens and HeartFlow. Dr. Maurovich-Horvat has been a shareholder of Neu-mann Medical Ltd. Dr. Einstein has previously received grants from NIH, International Atomic Energy Agency, Canon Medical Systems, Roche Medical Systems, WL Gore, and GE Health care; consultant for WL Gore; on the Speakers Bureau for Ionetix; has received travel/accommodations/meeting expenses from HeartFlow; and is a stock-holder in Emergent BioSolutions Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.